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ABSTRACT
Background: The BREATHE study is a cross-sectional study of real-life patients with asthma and/
or COPD in Denmark and Sweden aiming to increase the knowledge across severities and
combinations of obstructive airway disease.
Design: Patients with suspicion of asthma and/or COPD and healthy controls were invited to
participate in the study and had a standard evaluation performed consisting of questionnaires,
physical examination, FeNO and lung function, mannitol provocation test, allergy test, and
collection of sputum and blood samples. A subgroup of patients and healthy controls had a
bronchoscopy performed with a collection of airway samples.
Results: The study population consisted of 1403 patients with obstructive airway disease (859
with asthma, 271 with COPD, 126 with concurrent asthma and COPD, 147 with other), and 89
healthy controls (smokers and non-smokers). Of patients with asthma, 54% had moderate-to-
severe disease and 46% had mild disease. In patients with COPD, 82% had groups A and B,
whereas 18% had groups C and D classified disease. Patients with asthma more frequently had
childhood asthma, atopic dermatitis, and allergic rhinitis, compared to patients with COPD,
asthma + COPD and Other, whereas FeNO levels were higher in patients with asthma and asthma
+ COPD compared to COPD and Other (18 ppb and 16 ppb vs 12.5 ppb and 14 ppb, p < 0.001).
Patients with asthma, asthma + COPD and Other had higher sputum eosinophilia (1.5%, 1.5%,
1.2% vs 0.75%, respectively, p < 0.001) but lower sputum neutrophilia (39.3, 43.5%, 40.8% vs
66.8%, p < 0.001) compared to patients with COPD.
Conclusions: The BREATHE study provides a unique database and biobank with clinical informa-
tion and samples from 1403 real-life patients with asthma, COPD, and overlap representing
different severities of the diseases. This research platform is highly relevant for disease pheno-
type- and biomarker studies aiming to describe a broad spectrum of obstructive airway diseases.
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Introduction
Randomized controlled trials (RCT) address important
questions such as risk/benefit profiles of new therapies,
but to improve internal validity they often report results
from narrow patient groups representing less than 2% of
the real-life patient population and thus hampers external
validity [1,2]. Real-life studies include patients with ‘real-
life’ co-morbidities, life-style factors, various inflammatory
phenotypes, and different adherence profiles, and these
patientsmay, therefore, elicit another response to treatment
compared with the highly selected patient groups included
in RCTs [3,4]. Therefore, real-life studies are pivotal to
address issues concerning the entire patient population
being exposed to the drugs investigated in RCTs [5,6].
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Examples of large patient–cohort studies within the
field of asthma are the U-BIOPRED and the SARP studies
[7,8] that included large samples of patients with severe
and mild to moderate asthma. The importance of these
multisite studies is considerable, but the focus has primar-
ily been towards increasing knowledge on severe asthma.
However, the frequency of severe asthma in an asthma
population is less than 10% [9,10], indicating that knowl-
edge about the majority of asthma patients must be gained
from other sources. The same goes for patients with COPD
and concurrent asthma and COPD, who generally have
been excluded from most asthma studies.
New treatment strategies are being developed these
years along with an increasing demand for individualized
disease management and new biomarkers to guide treat-
ment and follow-up and to assess comorbidities [11,12].
Therefore, in-depth knowledge of real-life respiratory
disease is required to develop a scientific, evidence-
based understanding of the underlying disease mechan-
isms driving the diseases in the entire patient population.
With the BREATHE research platform, we aimed to
develop a well-characterized and comprehensive database
and biobank with clinical data and samples from real-life
patients with different severities of obstructive airway dis-
ease as well as a reference population of healthy controls.
Methods
Design
The study was a multicentre, descriptive cross-sectional
clinical study recruiting real-life patients with asthma
and/or COPD and healthy controls from five clinical cen-
tres: two specialist care units in Eastern Denmark and one
specialist care unit plus two primary care units in Southern
Sweden. The recruitment period was 2 years (February
2017–February 2019). The study and all related study
documents were approved by the local ethics committees
(H-16047428, Denmark and Dnr 2016/1069, Lund
Sweden). All participants gave written informed consent
prior to the study (Helsinki declaration 1964–2014 50).
The study was not registered in a public domain.
Participants
The participants were either newly referred patients
with suspected asthma or COPD, or patients at
regular review for asthma or COPD at either specialist
care units or primary care clinics; or subjects recruited
as healthy controls. All healthy controls were
screened by an MD to ensure no present or former
respiratory disease. All participants underwent a base-
line visit (visit 1a+1b), and a subset of patients and
healthy controls underwent a bronchoscopy (visit 2)
(Figure S1). Inclusion and exclusion criteria are
described in the supplementary methods section.
Interview
Information on respiratory disease, allergy, family history
of atopic diseases, seasonal variation in lung and nasal
symptoms, and medication for respiratory diseases and/or
allergy was obtained. History of tobacco consumption was
recorded, and patients were classified as never smoker,
former smoker (smoke-free for at least the past 6 months),
or current smoker; the average number of pack-years was
calculated ((average number of daily cigarettes*years)/20).
Physical examination
All participants had a health check performed with a
focus on respiratory illness and co-morbidities –
including measurement of blood pressure, pulse, and
oxygen saturation (Visit 1). Nasal inspection for polyps
and swollen mucosa was performed followed by a nasal
swab of the meatus medius/medial concha.
Baseline measurements
Age, sex, weight, and height were recorded for all parti-
cipants. BMI was calculated as weight in kg/(height in
meters)^2.
Questionnaires
All patients answered 12 questionnaires regarding symp-
toms and disease-control (ACQ-5 [13], ACT [14], CAT
[15], Medical Research Council dyspnoea scale (mMRC))
[16], quality-of-life (SF12 [17], miniAQLQ [18],
miniRQLQ [19], CCQ [20], HADS [21]), and comorbid-
ities (Nijmegen [22], SNOT22 [23], Epworth Sleepiness
Scale (ESS) [24]) (Table 3). Patients were also asked about
hospital referrals and visits to GP or specialist due to
exacerbations, the onset of disease and childhood symp-
toms as well as socio-economic factors such as income
and education level. The presence of chronic rhinosinu-
sitis (CRS) was deduced from answers to the SNOT22
questionnaires as described [25] using a cut-off ≥3 and
based on the nasal inspection patients with CRS were
classified with (w) or without (s) nasal polyps (NP), i.e.
CRSwNP or CRSsNP.
Pre-medication
Prior to respiratory testing, participants were asked not to
use short-acting β2 agonist (SABA) for 8 h, inhaled
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corticosteroid (ICS) for 12 h, long-acting β2 agonists
(LABAs), long-acting muscarinic antagonists (LAMA),
short-acting muscarinic antagonists (SAMA), theophylline
or smoking for 24 h, leukotriene-antagonist for 1 day and
antihistamines for 72 h before the visit. Patients on a stable
dose of oral corticosteroids (OCS) could continue
their use.
Exhaled nitric oxide
Fractional exhaled nitric oxide (FeNO) was analysed
using NIOX VERO® equipment (Aerocrine AB, Solna,
Sweden) and the mean of three measurements was
recorded [26]. In approximately one-third of the parti-
cipants, alveolar NO and bronchial flow were measured
using Medisoft FENO+ (Sorinnes, Belgium).
Spirometry
Spirometry was performed according to the standards
specified by the ERS and ATS [27]. Briefly, FEV1 and
FVC were measured three times, with differences between
the two largest FEV1 values being ≤0.150 L and the two
largest FVC values being ≤0.150 L, using a Jaeger spirom-
eter with ECCS 93 reference values (Intramedic®, Gentofte,
Denmark).
Static lung volume
Participants recruited from the specialist care units had
measurements of total lung capacity (TLC) and diffusion
capacity for carbon monoxide (DLCO) performed using
Jaeger® box (Intramedic®, Gentofte, Denmark) according
to the standards specified by the ERS and ATS [28].
Predicted normal values of FEV1, FVC, FEV1/FVC
ratio based on sex, height, weight, and age were calculated
using reference values ECCS 93 [29].
Reversibility test
Patients with an FEV1 <70% predicted performed a
short-acting β2 reversibility test. FEV1 was measured
at baseline and 15 min after 0.8 mg of salbutamol
(4 × 0.2 mg or 8 × 0.1 mg). The test was considered
positive if FEV1 increased with at least 12% (and
200 ml) from baseline [30].
Mannitol bronchial provocation
A mannitol test was performed in participants with an
FEV1 ≥70% of predicted (Aridol™; Pharmaxis, Frenchs
Forest, Australia). A positive test response indicating
airway hyperresponsiveness (AHR) was defined as a
15% fall or more in FEV1 at a total dose of ≤635 mg.
Sensitivity to mannitol was reported as PD15, i.e. the
mannitol dose that results in a 15% fall or more in
FEV1, and responsiveness was reported as a response–
dose ratio (RDR) defined as percent fall in FEV1/
cumulative dose of mannitol [31].
Allergy testing and atopy
Specific IgEs or skin prick test (ALK-Abello®, Hørsholm)
was performed with a standard panel of 10 aeroallergens.
The specific IgE test was considered positive if at least one
of the specific IgE levels >0.35 kU/L and the skin prick test
was considered positive if at least one wheal was >3 mm
observed after 15 min. Atopy was defined as a positive-
specific IgE or skin prick test.
Disease severity and diagnosis
Severity of asthmawas classified according to GINA guide-
lines [30,32] and COPD was classified according to GOLD
guidelines [33]. A diagnosis of asthma, COPD, or concur-
rent asthma and COPD (termed ‘asthma + COPD’ here-
after) was based on thorough medical history, clinical
evaluation, and relevant lung function and bronchoprovo-
cation tests. Patients in whom a diagnosis of asthma or
COPD could not be made were allocated to the ‘Other’
group.
Biological samples
Blood samples and nasal swabs (ESWAB 482C, Copan,
Italy) were obtained from all participants. Leukocyte
and differential cell counts were performed and blood
eosinophils >0.3 × 10^9 cells/L was used as a cut-off to
determine the presence of eosinophilic inflammation in
the blood [34]. For the subset of participants under-
going bronchoscopy, bronchoalveolar lavage (BAL)-
fluid, brushings and mucosa biopsies, faecal, urine,
and saliva samples were obtained.
Sputum induction and cell count
Sputum was obtained either spontaneously, immedi-
ately after mannitol testing or induced using isotonic
(0.9%) or incremental concentrations of NaCl solutions
(3%, 4%, and 5%) and processed as described [35].
Four hundred non-squamous cells were counted, and
the percentages of epithelial cells, eosinophils, neutro-
phils, macrophages and lymphocytes were listed. A cut-
off of 3% for eosinophils and 61% for neutrophils was
used for sputum inflammatory phenotyping [36,37].
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Data were entered in an electronic case report form
(SecureCRF®, Copenhagen, Denmark).
Statistical analysis
Continuous variables were reported as mean with stan-
dard deviations for normally distributed variables, while
non-normally distributed variables were reported as
median with 25th and 75th percentiles. Continuous vari-
ables were tested using Kruskal–Wallis test, while catego-
rical variables were tested using Chi-square test. Monte
Carlo simulation was used if Chi-square approximation
was not met (expected cell counts <5), thereby comparing
the observed data to random samples.
Analyses were performed using SAS Studio (SAS
Institute, Cary, NC, USA).
Results
A total of 1492 participants were recruited over a 2-
year period: 859 patients with asthma, 271 patients
with COPD, 126 patients with asthma + COPD, and
89 healthy controls (Figure 1 and Tables 1 and 2).
Moreover, 147 patients did not have asthma or
COPD (‘Other’ group; supplementary Table S1).
The participants were recruited from Denmark
(n = 906) and Sweden (n = 591) with approximately
one-third of the participants from general practitioners
and two-thirds from outpatient clinics (Table 1). The
age distribution was equal between sites except for
participants from Copenhagen (DK), who were
younger (p < 0.001) and BMI was higher in patients
from Naestved (DK) (p = 0.003).
Gender distribution was equal across groups (Table 2).
The BMI did not differ between patients with asthma and
COPD, whereas FEV1 percent predicted (91% vs 56%,
p < 0.001) was higher in patients with asthma than those
with COPD.
In general, patients reported a high degree of
respiratory symptoms (Table 3). The symptom burdens
depicted by ACQ-5, ACT, CAT, and mMRC scores
were higher in patients with COPD than in those
with asthma (p < 0.01, all), independent of the origin
of the questionnaire. Among the COPD patients, spe-
cific scores of CAT >10 and mMRC ≥2 were found in
70% and 87% of the patients, respectively, and among
patients with asthma, uncontrolled disease indicated by
ACQ >1.5 and ACT ≤19 was found in 44% and 49%,
respectively.
Based on the quality-of-life (QoL) related question-
naire SF-12, COPD and asthma + COPD patients, in
general, reported a worse health-status regarding the
physical (PCS), but the mental component was com-
parable across groups. The same tendency was seen in
the activity components from MiniAQLQ, MiniRQLQ,
and CCQ, which indicated a better health status for
patients with asthma and Other compared to patients
with COPD and asthma + COPD (p < 0.01, all).
The comorbidity-related questionnaire scores from
SNOT-22 and Nijmegen did not differ significantly
between the four patient groups (p = 0.45 and
p = 0.60, respectively), and although the score for
Epworth sleepiness scale was significantly higher in
Figure 1. Consort flow diagram. Sputum was collected at specialist clinical sites only, not in primary care units; therefore, sputum
samples do not exist for all participants. Bronchoscopy was performed in a subgroup of participants. Healthy controls: smokers and
non-smokers. Concurrent asthma and COPD: asthma + COPD.
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patients with asthma compared to COPD, asthma +
COPD and Other (p = 0.001), all scores were within the
normal range.
Comorbidities such as cardiovascular, metabolic, and
orthopaedic disorders were generally more frequent in
patients with COPD and asthma + COPD compared to
patients with asthma and Other (all comparisons:
p < 0.01), whereas childhood asthma (36%), atopic der-
matitis (26%), and allergic rhinitis (55%) were more pre-
valent in patients with asthma compared to the three
other patient groups (p < 0.001 for all) (Table 4).
Furthermore, chronic rhinosinusitis without nasal polyps
(CRSsNP) was more frequently observed in asthma than
in the three other patient groups (p < 0.001).
AHR to mannitol, dose–response ratio (RDR)
(p < 0.001, both) and PD15 (p = 0.04) differed across
the four groups but were not significantly different
between patients with asthma and COPD (Table 5). A
positive mannitol test was found in 331 (48%) of the
695 tested patients with asthma and in 30/47 (64%)
tested patients with asthma + COPD. Reversibility was
more frequent in patients with asthma and asthma +
COPD than in those with COPD and Other (45% and
47% vs 21% and 8%, p < 0.001).
The prevalence of blood eosinophilia (>0.3*109/L) was
not different in patients with asthma, COPD, or asthma +
COPD but was lower in the Other group (Table 5).
However, FeNO levels were significantly higher in
patients with asthma and asthma + COPD (18.0 and 16
ppb) compared to COPD and Other (12.5 ppb and
14.5 ppb). When assessing sputum eosinophils, we
found a higher level in patients with asthma, asthma +
COPD and Other compared to those with COPD (1.5%,
1.5%, 1.2% vs 0.75%, p < 0.001), whereas patients with
Table 1. Distribution of patients between countries and clinical sites in the BREATHE study.
Copenhagen, DK Naestved, DK Lund, SE General practitioners, SE p-Value
Subjects (n) 675 229 108 483
Age 44 (28–60) 62 (50–70) 63 (46–69) 57 (44–70) <0.001
BMI 26 (5) 27 (6) 26 (5) 26 (4) 0.003
Asthma (n) 442 (65%) 70 (31%) 30 (28%) 317 (66%) <0.001
COPD (n) 60 (9%) 98 (43%) 33 (31%) 80 (17%)
Asthma+COPD (n) 48 (7%) 38 (17%) 4 (4%) 36 (8%)
Other (n) 84 (12%) 20 (9%) 10 (9%) 33 (7%)
Healthy controls (n) 40 (6%) 3 (1%) 30 (28%) 16 (3%)
Data are presented as numbers (n), n/N (%), mean±SD, or median (interquartile range, 25th–75th).
Table 2. Baseline variables.
Asthma COPD Asthma + COPD Other Healthy p-Value p-Value#
Subjects n 859 271 126 147 89
Gender (females) 480 (56%) 155 (57%) 75 (60%) 89 (61%) 57 (64%) 0.49 0.66
Age (years) 45 (29–58) 68 (62–74) 64 (56–72) 51 (33–65) 42 (26–58) <0.001 <0.001
Height (cm) 173 (10) 169 (10) 171 (10) 173 (9) 172 (10) <0.001 <0.001
Weight (kg) 79 (17) 75 (18) 82 (19) 76 (16) 74 (16) <0.001 0.003
BMI (kg/m2) 26.2 (5) 26.2 (6) 27.9 (6) 25.1 (4) 24.8 (4.5) <0.001 0.94
BMI >30 158 (18%) 55 (20%) 37 (29%) 17 (12%) 10 (11%) 0.001 0.49
Smoking status
Never smoker 517 (60%) 5 (2%) 7 (6%) 79 (54%) 53 (60%) <0.001 <0.001
Former smoker 271 (31%) 182 (67%) 86 (68%) 52 (35%) 12 (13%)
Current smoker 66 (8%) 84 (31%) 33 (26%) 16 (11%) 21 (24%)
Pack-years 0 (0–5) 40 (25–50) 30 (20–42) 0 (0–12.5 0 (0–21) <0.001 <0.001
Pack-years among
former & current
smokers
8 (4–20) 40 (25–50) 30 (20–44) 15 (5–30) 30 (5–43) <0.001 <0.001
Exacerbations in
previous year
0 (0–1) 0 (0–1) 0 0 0 <0.001 0.29
Atopy 452/828 (55%) 28/215 (13%) 44/112 (39%) 41/138 (30%) 9/86 (10%) <0.001 <0.001
Total IgE (10^3 IU/L) 67 (22–219) 39 (11–162) 68 (16.9–156) 28 (9–63) 26.5 (13.7–66.5) <0.001 0.01
Lung function
FEV1 (L) 3.1 (0.94) 1.49 (0.66) 1.87 (0.70) 3.22 (1.08) 3.47 (0.92) <0.001 <0.001
FEV1% predicted 91 (80–101) 55.9 (41–71) 68.5 (54–80) 100 (88–109) 102 (91–110.5) <0.001 <0.001
FVC (L) 4.02 (3.32–4.81) 2.57 (1.99–3.20) 2.9 (2.4–3.8) 3.97 (3.28–4.87) 4.28 (3.46–5) <0.001 <0.001
FVC % predicted 100 (88–111) 79.95 (68–92.45) 88.5 (76–702.7) 104.5 (92–114) 103 (95.5–116.5) <0.001 <0.001
TLC (L) 6.21 (5.46–7.38) 6.63 (5.52–7.95) 6.53 (5.77–7.62) 6.08 (5.3–7.22) 5.88 (5.24–6.79) 0.003 0.004
TLC % predicted 104.5 (17) 116.3 (22.03) 116.3 (20.3) 103.4 (19.4) 99.77 (8.13) <0.001 <0.001
DLCO (mmol/min/
kPa)
8.23 (7.08–10.09) 4.29 (2.78–5.69) 5.63 (3.80–7.28) 7.8 (6.48–9.97) 7.05 (6.42–7.73) <0.001 <0.001
DLCO % predicted 87.8 (15) 53.5 (20.6) 66.2 (17.6) 83.3 (18) 83.9 (16) <0.001 <0.001
Data are presented as numbers (n), n/N (%), mean±SD, or median (interquartile range). BMI: body mass index; FEV1: forced expiratory volume in 1 sec; FVC:
forced vital capacity; TLC: total lung capacity; DLCO: diffusion capacity for CO; NA: not applicable. #Asthma versus COPD.
EUROPEAN CLINICAL RESPIRATORY JOURNAL 5
COPD had higher sputum neutrophil levels compared to
the three other patient groups (66.8% vs 39.3%, 43.5%
and 40.8%, p < 0.001) (Table 5, suppl. Figures S2 and S3).
Atopy was significantly more frequent in patients
with asthma than in patients with COPD (55% vs
13%, p < 0.001) (supplementary Table S2).
Disease severity based on GINA classification for
patients with asthma (Table 6) showed that 54% had
moderate to severe disease whereas 46% had mild dis-
ease. For patients with COPD, the GOLD classification
showed that 82% had groups A and B disease, whereas
18% had groups C and D disease.
Discussion
The current study represents, to our knowledge, the
largest clinical real-life study on patients with obstructive
airway diseases: asthma, COPD, or concurrent asthma
and COPD with different degrees of severity and pheno-
types. With this study, we have generated a research
Table 3. Questionnaires.
Asthma COPD Asthma + COPD Other p-value p-value#
Subjects (n) 859 271 126 147
ACQ-5 1.5 (1.2) 1.7 (1.2) 1.7 (1.2) 1.8 (1.0) <0.001 0.007
ACQ-5 > 1.5 375 (44%) 150 (55%) 64 (51%) 51 (35%) <0.001 0.0002
ACT 18.5 (4.8) 17.6 (4.8) 17.5 (4.9) 16.5 (3.8) <0.001 0.004
ACT ≤ 19 420 (49%) 165 (61%) 68 (54%) 66 (45%) 0.0006 0.0001
CAT 11.1 (7.7) 15.0 (7.2) 13.4 (8) 10.2 (4.9) <0.001 <0.001
CAT > 10 396 (46%) 190 (70%) 64 (51%) 58 (40%) <0.001 <0.001
mMRC 1.8 (0.8) 2.6 (1.0) 2.3 (1) 1.3 (0.5) <0.001 <0.001
mMRC ≥2 486 (57%) 235 (87%) 97 (77%) 62 (42%) <0.001 <0.001
SF12
PCS 46.3 (9.8) 38.4 (10.6) 41.3 (10.6) 46.6 (8.4) <0.001 <0.001
MCS 51.0 (9.9) 51.7 (9.2) 52.5 (10.2) 55.1 (3.3) 0.09 0.5
miniAQLQ overall 5.47 (1.10) 5.44 (1.01) 5.42 (1.08) 5.85 (0.99) <0.001 0.31
Symptoms 5.26 (1.24) 5.47 (1.10) 5.28 (1.24) 5.59 (1.16) 0.01 0.048
Activity 5.78 (1.16) 4.95 (1.40) 5.40 (1.36) 6.01 (1.14) <0.001 <0.001
Emotional 5.40 (1.41) 5.75 (1.30) 5.43 (1.44) 5.90 (1.25) <0.001 <0.001
Environment 5.48 (1.42) 5.75 (1.29) 5.73 (1.28) 6.03 (1.20) <0.001 0.003
miniRQLQ overall 1.42 (1.02) 1.20 (0.85) 1.24 (0.87) 1.21 (0.99) 0.006 0.008
Activity 1.33 (1.27) 1.61 (1.42) 1.54 (1.33) 1.20 (1.23) 0.009 0.01
Eyes 0.95 (1.17) 0.75 (1.04) 0.79 (0.91) 0.81 (1.13) 0.02 0.005
Non-nose and eyes 1.57 (1.29) 1.34 (1.11) 1.49 (1.26) 1.40 (1.29) 0.10 0.04
Nose 1.68 (1.37) 1.10 (1.09) 1.12 (1.10) 1.37 (1.31) <0.001 <0.001
Practical 1.64 (1.43) 1.17 (1.29) 1.24 (1.15) 1.35 (1.38) <0.001 <0.001
CCQ
Activity 3.7 (3.9) 7.0 (4.9) 5.3 (4.7) 3.8 (2.4) <0.001 <0.001
Emotional 2.4 (2.7) 3.0 (2.9) 2.9 (2.9) 3.7 (2.3) <0.001 0.0006
Symptoms 5.7 (4.6) 6.4 (4.2) 6.3 (4.7) 9 (5.0) 0.002 0.0023
HADS
HADS depression 2.7 (3.0) 3.0 (2.8) 2.9 (3.4) 1.7 (1.5) 0.04 0.01
HADS anxiety 4.96 (3.9) 4.4 (3.4) 7.9 (6.7) 3.6 (2.5) 0.39 0.14
Nijmegen 15.5 (9.7) 15.6 (8.7) 15.8 (9.4) 15 (7.8) 0.60 0.42
SNOT22 20.0 (13.9) 18.9 (12.4) 18.1 (12.3) 7.5 (10.6) 0.45 0.51
ESS 6.24 (4.2) 5.3 (4.0) 5.7 (3.5) 5.6 (1.1) 0.001 <0.001
Data are presented as mean±SD. ACQ-5: Asthma Control Questionnaire; ACT: Asthma Control Test; CAT: COPD Assessment Test; mMRC: Medical Research
Council dyspnea scale; SF-12: Health condition questionnaire; miniAQLQ: Mini Asthma Quality of Life Questionnaire; miniRQLQ: Mini Rhinoconjunctivitis
Quality of Life Questionnaire; CCQ: Clinical COPD Questionnaire; HADS: Hospital Anxiety and Depression Scale; Nijmegen: Hyperventilation; SNOT22: Sino-
Nasal Outcome Test; ESS: Epworth sleepiness scale. Asthma versus COPD.
Table 4. Comorbidities.
Asthma COPD Asthma+COPD Other p-Value p-Value#
Subject n 859 271 126 147
Mental 37 (4%) 18 (7%) 8 (6%) 2 (1%) 0.07 0.12
Cardiovascular 86 (10%) 106 (39%) 40 (32%) 25 (17%) <0.001 <0.001
Metabolic 55 (6%) 49 (18%) 18 (14%) 16 (11%) <0.001 <0.001
Ortopedic 18 (2%) 18 (7%) 9 (7%) 1 (0.7%) <0.001 0.0002
Other 95 (11%) 37 (14%) 19 (15%) 21 (14%) 0.37 0.25
Childhood asthma 311 (36%) 17 (6%) 22 (18%) 18 (12%) <0.001 <0.001
CRSwNPc 5 (0.6%) 0 0 0 0.30 0.33
CRSsNPc 202 (24%) 26 (1%) 15 (12%) 26 (18%) <0.001 <0.001
Atopic dermatitits 226 (26%) 39 (14%) 19 (15%) 27 (18%) <0.001 <0.001
Allergic rhinitis 476 (55%) 94 (35%) 53 (42%) 47 (32%) <0.001 <0.001
Severe asthmaa 120 (14%) 3 (1%) 13 (10%) 0 <0.001 <0.001
Dysfunctional breathingb 174 (20%) 46 (17%) 21 (17%) 19 (13%) 0.14 0.23
CRS: chronic rhinosinusitis. aAccording to ATS/ERS guidelines. bNijmegen score >23. cDeduced from SNOT-22. #Asthma versus COPD.
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platform with a unique database and biobank from 1492
well-characterized subjects including patients from both
specialized centres and from primary care centres.
Patients were recruited from both capital cities and
more rural areas, and include obese and non-obese, smo-
kers and non-smokers, as well as control subjects consist-
ing of healthy controls, healthy smokers and patients
referred with asthma or COPD symptoms but where
the diagnosis cannot be confirmed, many of which are
unique features of our study.
In this population, we found that patients with asthma
and asthma + COPD had higher levels of FeNO and
sputum eosinophils compared to patients with COPD;
moreover, patients with asthma were more atopic, more
frequently had chronic rhinosinusitis and childhood
asthma and were younger than patients with COPD,
asthma + COPD and Other. Conversely, patients with
COPD and asthma + COPD had a higher frequency of
comorbidities such as cardiovascular and metabolic disor-
ders, lower quality of life, and patients with COPD had
higher levels of sputum neutrophils. Systemic inflamma-
tion measured with blood eosinophils did not differ
between patients with asthma, COPD, and asthma +
COPD, which contrasts with the general assumption that
asthma is more eosinophilic driven whereas COPD is
neutrophilic; however, this finding is in line with previous
observations [38].When further characterizing the inflam-
matory phenotypes in sputum, we found that patients with
asthma and asthma + COPD more often had sputum
eosinophilic inflammation than patients with COPD and
Other, suggesting that even though the blood eosinophil
counts were comparable, patients with asthma and asthma
+ COPD more frequently had signs of localized eosino-
philic inflammation in the airways compared to patients
with COPD andOther. However, sputum eosinophilia was
also observed in some patients with COPD, which points
to the existence of eosinophilic COPD and highlights the
importance of airway sampling when assessing inflamma-
tory phenotypes in airway disease.
The frequency of CRSwNP in patients with asthma
was lower than expected probably due to the high
fraction of patients with mild to moderate disease
with a low degree of blood eosinophils. Former studies
on CRSwNP have primarily been performed in severe
asthma or in severe CRS and in both cases, the fre-
quency of polyps was substantially higher than in unse-
lected, real-life patients [39–41].
Airway hyperresponsiveness (AHR) measured with a
mannitol challenge test did not differ between patients
with asthma and COPD, but was higher in patients with
asthma + COPD and lower in the Other group – however,
only very few patients with COPD had the test performed
due to low level of lung function (FEV1 < 70%), whichmay
explain these findings. Moreover, COPD patients with
normal lung function and with a significant smoking his-
tory could have airway inflammation with mast cells
resembling the inflammation in patients with asthma
[42,43]. Likewise, AHR to mannitol was also observed in
four healthy asymptomatic smokers, which may be
explained by the fact that inflammation caused by smoking
may be sensitive to the mannitol test, as previously
described [44]. These findings suggest that categorizing
the diseases as asthma, COPD, or asthma + COPD based
on AHR test results may be too simple, since pathology,
inflammatory phenotypes, and test results tend to over-
lap [45].
This study is a real-life GP/specialist-based study
that included patients referred or followed in these
clinical settings and it is therefore designed to show
the disease burden in these patients and not in a
broader epidemiological setting. The patients, in gen-
eral, reported a high degree of respiratory symptoms,
which may reflect the fact that approximately two-
thirds of the patients were recruited after being referred
for specialist evaluation. The group of patients termed
Other had in-between levels of inflammation, atopy,
chronic rhinosinusitis and childhood asthma, few
comorbidities, average age, normal weight, and normal
Table 6. GOLD classification of patients with COPD and GINA classification of patients with asthma.
GOLD classification of patients with COPD
GOLD 1 GOLD 2 GOLD 3 GOLD 4 TOTAL
Group A, n (%) 1 (0.5) 4 (1.8) 3 (1.4) 1 (0.5) 9 (4.1)
Group B, n (%) 16 (7.2) 104 (47.1) 41 (18.6) 11 (5) 172 (77.8)
Group C, n (%) 0 (0) 0 (0) 1 (0.5) 0 (0) 1 (0.5)
Group D, n (%) 1 (0.5) 18 (8.1) 16 (7.2) 4 (1.8) 39 (17.6)
Total, n (%) 18 (8.1) 126 (57.0) 61 (27.6) 16 (7.2) 221
COLD guidelines 2019
GINA classification of patients with asthmaa
GINA step GINA 1 + 2, n (%) GINA 3, n (%) GINA 4, n (%) GINA 5, n (%) Total, n
Patients 239 (46%) 80 (16%) 86 (17%) 107 (21%) 512
GINA guidelines 2019. aOnly Danish patients, since medication doses were not available for Swedish patients.
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lung function but with many symptoms. Some had
cough or dyspnoea, but most were classified with
unspecific respiratory symptoms or negative bronchial
provocation tests. They may represent a cluster char-
acterized by being highly symptomatic but with a pau-
cigranulocytic phenotype, like the cluster suggested by
Haldar et al. [46], who found a group of asthma
patients, who reported having many respiratory symp-
toms but a low degree of inflammation.
This study offered all patients with a similar medical
work-up regardless of whether the referral diagnosis was
asthma, COPD, or asthma + COPD. For example, all
patients completed a range of questionnaires without pre-
selecting them as patients with either asthma and/or
COPD, which provides a unique opportunity to further
validate these questionnaires in a broader, more real-life
setting where the entire spectrum of patients with obstruc-
tive airway disease is represented. Moreover, since asthma
and COPD represent a continuum of airway obstruction
with heterogenous inflammatory mediators, deciding on
an evaluation program based on a referral note may not be
the optimal way to evaluate patients. Also, the traditional
classification of these diseases based on clinical manifesta-
tions that does not distinguish between cellular and mole-
cular mechanisms in the evaluation of obstructive airway
disease may not be up to date.
Limitations to our study could be that each participat-
ing centre had its own specialist focus, which affected the
patient flow and resulted in an unequal distribution of
patient groups from the clinical sites. On the other hand,
this approach allowed each centre to focus on recruiting
patients with different severities and phenotypes of the
diseases; moreover, only a few doctors at each site exam-
ined all the patients, which contributed to a uniform way
of interpreting test results and diagnosing patients.We do
recognize that despite thorough medication history and
examinations, lung function tests and questionnaires,
diagnosing obstructive airway diseases can be challenging
[45,47]. In this study, we chose to use mannitol for
bronchial provocation tests, which has a high specificity
but low sensitivity compared to methacholine, and we are
therefore at risk of under-diagnosing asthma [48].
Another limitation of our study is the bronchoscopy
population, which was smaller and more selected than
the general study population and may not represent the
entire severity spectrum of the diseases.
Standardization of clinical and laboratory procedures
across borders can be challenging, and tomeet these issues,
we translated all standard operating procedures (SOPs) to
bothDanish and Swedish, had regularmeetings and central
scientific coordinators in each country that ensured har-
monization of procedures. However, despite these efforts,
lack of laboratory facilities at the primary care centres
prevented the collection of processed sputum from these
sites.
In conclusion, this clinical study on real-life patients
with obstructive airway disease, who are thoroughly
examined independently of traditional labelling, can
be the future basis of cellular and biomarker evaluation
of patients with obstructive airway diseases managed in
the everyday clinic.
Acknowledgments
This paper is presented by the BREATHE study group.
We would like to thank all the members of the five recruiting
sites for their effort and dedication in recruiting patients and the
laboratory technicians Ôznur Turan, Merve Melike Yilmaz and
Lene W Pedersen from Respiratory Research Unit, Bispebjerg
UniversityHospital, Copenhagen, DK, for counting of all sputum
samples.
Thanks to Pharmaxis for providing the Aridol kits for the
Swedish patients. And thanks to Professor Elizabeth F. Juniper,
UK, for permission to use the ACQ-5, Mini-AQLQ and Mini-
RQLQ questionnaires. ThemMRC questionnaire was used with
the permission of the Medical Research Council.
Disclosure statement
V. Backer has nothing to disclose. D.K. Klein has nothing to
disclose. U. Bodtger has nothing to disclose. K. Romberg reports
personal fees for lecturing and/or attending advisory board from
AstraZeneca, ALK, Boehringer, Chiesi, GSK, Meda, Novartis,
and from Teva, outside the submitted work. C. Porsbjerg has
nothing to disclose. Jonas S Erjefält has nothing to disclose.
Karsten Kristiansen has nothing to disclose. R. Xu has nothing
to disclose. Alexander Silberbrandt has nothing to disclose.
Laurits Frøssing has nothing to disclose. Morten Hvidtfeldt has
nothing to disclose. N. Obling reports personal fees from
AstraZeneca, other from Boehringer Ingelheim Denmark A/S,
outside the submitted work. Linnea Jarenbäck has nothing to
disclose. Abir Nasr has nothing to disclose. Ellen Tufvesson has
nothing to disclose. Michiko Mori has nothing to disclose.
Matilde Winther-Jensen has nothing to disclose. Lisa Karlsson
has nothing to disclose. Ulf Nihlén has nothing to disclose.
Thomas Veje Flintegaard has nothing to disclose. L. Bjermer
reports personal fees for lecturing and/or attending advisory
board from AstraZeneca, ALK, Boehringer, Chiesi, GSK,
Novartis, Sanofi and from Teva, outside the submitted work.
Funding
This work was supported by the Interreg ÖKS [NYPS20201002];
AstraZeneca [unrestricted grant] and TEVA [unrestricted grant].
The funders had no active role in the study.
Notes on contributors
Vibeke Backer is clinical professor at the University of
Copenhagen, Denmark. She obtained her degree in medicine
EUROPEAN CLINICAL RESPIRATORY JOURNAL 9
from the University of Copenhagen in 1983. She has
authored more than 350 publications.
Ditte Klein is a human biologist, she received her degree in 2005
from the University of Copenhagen.
Uffe Bødtger is a medical doctor, he received his degree in 1997
from the University of Copenhagen.
Kerstin Romberg is a medical doctor, she received her degree in
1981 from Lunds University.
Celeste Porsbjerg is a medical doctor, she received her degree in
1996 from the University of Copenhagen. Since 2019 she is a
Professor in the field of Severe Asthma.
Jonas S Erjefält is a biologist and received his degree in 1992
from the LundUniversity. Since 2011 he is a Professor in the field
of Respiratory Immunology and Inflammation Research.
Karsten Kristiansen is a biologist and received his degree in
1972 from the University of Copenhagen. Since 2004 he is a
Professor in the field of Metagenomics.
Ruiqi Xu is a biologist and she received her degree in 2009 from
University of Copenhagen.
Alexander Silberbrandt is amedical doctor and graduated from
theUniversity of Copenhagen in 2014. Currently he is writing his
PhD thesis on the impact of smoking in severe eosinophilic
asthma.
Laurits Frøssing is a medical doctor, he received his degree in
2014 from the University of Copenhagen.
Morten Hvidtfeldt is a medical doctor, he received his degree
in 2014 from the University of Copenhagen.
Nicolai Obling is a medical doctor since 2011 and is cur-
rently a Specialist Registrar and PhD fellow in Respiratory
Medicine.
Linnea Jarenbäck received her degree in biomedicine in 2010
from Lund University.
Abir Nasr is a technologist and received a degree of Masters
in Medical Diagnostics: Functional Imaging in 2017 from the
University of Örebro.
Ellen Tufvesson is a biologist, she received her degree in 1997
from the Lund University, Sweden.
Michiko Mori received her degree in biomedicine in 2006
from Lund University.
Matilde Winther-Jensen is an evolutionary biologist with a
Ph.D. degree in epidemiology of treatment patterns in car-
diac arrest patients; which she received in 2018 from the
University of Copenhagen.
Lisa Karlsson received her degree in biomedicine in 2005
from Linköping University.
Ulf Nihlén is a medical doctor, he received his degree in 1979
from the Lund University, Sweden.
Thomas Veje Flintegaard is a molecular biologist, he
received his degree in 2006 from the University of
Southern Denmark.
Leif Bjermer is professor at Lund University, Sweden. He
obtained his degree in medicine from University of Umeå
(Sweden) in 1984. He has authored more than 320
publications.
ORCID
Uffe Bodtger http://orcid.org/0000-0002-1231-9209
References
[1] Costa DJ, Amouyal M, Lambert P, et al. How repre-
sentative are clinical study patients with allergic rhi-
nitis in primary care? J Allergy Clin Immunol.
2011;127:920–6.e1.
[2] Herland K, Akselsen J-P, Skjonsberg OH, et al. How
representative are clinical study patients with asthma or
COPD for a larger “real life” population of patients with
obstructive lung disease? Respir Med. 2005;99:11–19.
[3] Price D, Brusselle G, Roche N, et al. Real-world research
and its importance in respiratory medicine. Breathe
(Sheffield, England). 2015;11:26–38.
[4] Roche N, Reddel H, Martin R, et al. Quality standards
for real-world research. Focus on observational database
studies of comparative effectiveness. Ann Am Thorac
Soc. 2014;11(Suppl 2):S99–104.
[5] Saturni S, Bellini F, Braido F, et al. Randomized con-
trolled trials and real life studies. Approaches and meth-
odologies: a clinical point of view. Pulm Pharmacol
Ther. 2014;27:129–138.
[6] Price D, Hillyer EV, van der Molen T. Efficacy versus
effectiveness trials: informing guidelines for asthma man-
agement. Curr Opin Allergy Clin Immunol. 2013;13:50–57.
[7] Teague WG, Phillips BR, Fahy JV, et al. Baseline fea-
tures of the Severe Asthma Research Program (SARP
III) cohort: differences with age. J Allergy Clin Immunol
Pract. 2018;6:545–554.e4.
[8] Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and
inflammatory characteristics of the European U-
BIOPRED adult severe asthma cohort. Eur Respir J.
2015;46:1308–1321.
[9] von BulowA, KriegbaumM, Backer V, et al. The prevalence
of severe asthma and low asthma control among Danish
adults. J Allergy Clin Immunol Pract. 2014;2:759–767.
[10] Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J.
1998;12:1209–1218.
[11] Darveaux J, Busse WW. Biologics in asthma–the next
step toward personalized treatment. J Allergy Clin
Immunol Pract. 2015;3:152–160. quiz 161.
[12] Barnes PJ. New anti-inflammatory targets for chronic
obstructive pulmonary disease. Nat Rev Drug Discov.
2013;12:543–559.
[13] Juniper EF, Svensson K, Mork A-C, et al. Measurement
properties and interpretation of three shortened ver-
sions of the asthma control questionnaire. Respir Med.
2005;99:553–558.
[14] Nathan RA, Sorkness CA, Kosinski M, et al. Development
of the asthma control test: a survey for assessing asthma
control. J Allergy Clin Immunol. 2004;113:59–65.
10 V. BACKER ET AL.
[15] Jones PW, Harding G, Berry P, et al. Development and
first validation of the COPD assessment test. Eur Respir
J. 2009;34:648–654.
[16] Council MR. Medical research council dyspnoea scale.
2016-12-01. Available from: https://mrc.ukri.org/
research/facilities-and-resources-for-researchers/mrc-
scales/mrc-dyspnoea-scale-mrc-breathlessness-scale/.
[17] Jenkinson C, Layte R. Development and testing of the
UK SF-12 (short form health survey). J Health Serv Res
Policy. 1997;2:14–18.
[18] Juniper EF, Guyatt GH, Cox FM, et al. Development
and validation of the mini asthma quality of life ques-
tionnaire. Eur Respir J. 1999;14:32–38.
[19] Juniper EF, Thompson AK, Ferrie PJ, et al.
Development and validation of the mini rhinoconjunc-
tivitis quality of life questionnaire. Clin Exp Allergy.
2000;30:132–140.
[20] Damato S, Bonatti C, Frigo V, et al. Validation of the
clinical COPD questionnaire in Italian language. Health
Qual Life Outcomes. 2005;3:9.
[21] Zigmond AS, Snaith RP. The hospital anxiety and depres-
sion scale. Acta Psychiatr Scand. 1983;67:361–370.
[22] van Dixhoorn J, Folgering H. The Nijmegen Questionnaire
and dysfunctional breathing. ERJ Open Res. 2015;1:00001–
2015.
[23] Hopkins C, Gillett S, Slack R, et al. Psychometric valid-
ity of the 22-item sinonasal outcome test. Clin
Otolaryngol. 2009;34:447–454.
[24] Johns MW. A new method for measuring daytime slee-
piness: the Epworth sleepiness scale. Sleep. 1991;14:540–
545.
[25] Caminha GP, Pizzichini E, Lubianca Neto JF, et al.
Rhinosinusitis symptoms, smoking and COPD: preva-
lence and associations. Clin Otolaryngol. 2018;43:1560–
1565.
[26] American Thoracic Society; European Respiratory
Society recommendations for standardized proce-
dures for the online and offline measurement of
exhaled lower respiratory nitric oxide and nasal
nitric oxide. Am J Respir Crit Care Med. 2005;2005
(171):912–930.
[27] MillerMR, Hankinson J, BrusascoV, et al. Standardisation
of spirometry. Eur Respir J. 2005;26:319–338.
[28] Johnson DC. Importance of adjusting carbon monoxide
diffusing capacity (DLCO) and carbon monoxide trans-
fer coefficient (KCO) for alveolar volume. Respir Med.
2000;94:28–37.
[29] Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung
volumes and forced ventilatory flows. Report working
party standardization of lung function tests, European
community for steel and coal. official statement of the
European respiratory society. Eur Respir J Suppl
1993;16:5–40.
[30] GINA. Global initiative for asthma: asthma manage-
ment and prevention. Pract Nurse. 2019;2019:1–201.
[31] Anderson SD, Brannan J, Spring J, et al. A new method
for bronchial-provocation testing in asthmatic subjects
using a dry powder of mannitol. Am J Respir Crit Care
Med. 1997;156:758–765.
[32] Chung KF, Wenzel SE, Brozek JL, et al. International
ERS/ATS guidelines on definition, evaluation and treat-
ment of severe asthma. Eur Respir J. 2014;43:343–373.
[33] Singh D, Agusti A, Anzueto A, et al. Global strategy for
the diagnosis, management, and prevention of chronic
obstructive lung disease: the GOLD science committee
report 2019. Eur Respir J. 2019;53:1900164.
[34] Pavord ID, Korn S, Howarth P, et al. Mepolizumab
for severe eosinophilic asthma (DREAM): a multicentre,
double-blind, placebo-controlled trial. Lancet. 2012;380:
651–659.
[35] Bafadhel M, McCormick M, Saha S, et al. Profiling of
sputum inflammatory mediators in asthma and
chronic obstructive pulmonary disease. Respiration.
2012;83:36–44.
[36] Simpson JL, McElduff P, Gibson PG. Assessment and
reproducibility of non-eosinophilic asthma using
induced sputum. Respiration. 2010;79:147–151.
[37] Simpson JL, Scott R, Boyle MJ, et al. Inflammatory
subtypes in asthma: assessment and identification
using induced sputum. Respirology. 2006;11:54–61.
[38] Wijnant SRA, Lahousse L, De Buyzere ML, et al. Prevalence
of asthma and COPD and blood eosinophil count in a
middle-aged belgian population. J Clin Med. 2019;8:1122.
[39] Moore WC, Bleecker ER, Curran-Everett D, et al.
Characterization of the severe asthma phenotype by
the national heart, lung, and blood institute’s severe
asthma research program. J Allergy Clin Immunol.
2007;119:405–413.
[40] Radhakrishna N, Tay TR, Hore-Lacy F, et al. Profile of
difficult to treat asthma patients referred for systematic
assessment. Respir Med. 2016;117:166–173.
[41] Porsbjerg C, Menzies-Gow A. Co-morbidities in severe
asthma: clinical impact and management. Respirology.
2017;22:651–661.
[42] Ballarin A, Bazzan E, Zenteno RH, et al. Mast cell
infiltration discriminates between histopathological
phenotypes of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2012;186:233–239.
[43] Sverrild A, Bergqvist A, Baines KJ, et al. Airway responsive-
ness to mannitol in asthma is associated with chymase-
positive mast cells and eosinophilic airway inflammation.
Clin Exp Allergy. 2016;46:288–297.
[44] Stolz D, Anderson SD, Gysin C, et al. Airway reactiv-
ity to inhaled mannitol in cigarette smokers: a long-
itudinal study. Respir Med. 2007;101:1470–1476.
[45] Aaron SD, Vandemheen KL, FitzGerald JM, et al.
Reevaluation of diagnosis in adults with physician-diag-
nosed asthma. JAMA. 2017;317:269–279.
[46] Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis
and clinical asthma phenotypes. Am J Respir Crit Care
Med. 2008;178:218–224.
[47] von Bulow A, Backer V, Bodtger U, et al. Differentiation
of adult severe asthma from difficult-to-treat asthma -
outcomes of a systematic assessment protocol. Respir
Med. 2018;145:41–47.
[48] Backer V, Sverrild A, Ulrik CS, et al. Diagnostic work-
up in patients with possible asthma referred to a uni-
versity hospital. Eur Clin Respir J. 2015;2:27768.
EUROPEAN CLINICAL RESPIRATORY JOURNAL 11
